Stocks of Nektar Therapeutics (NASDAQ:NKTR) traded higher last session on Wall Street, down -1.96% to $1.00.
As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.60, we find $1.75. Given the previous closing price of $1.02, this indicates a potential upside of 71.57 percent. NKTR stock price is now 73.56% away from the 50-day moving average and -41.98% away from the 200-day moving average. The market capitalization of the company currently stands at $183.30M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Brokers who have rated the stock have averaged $2.35 as their price target over the next twelve months.
With the price target reduced from $1.50 to $1, Jefferies Upgraded its rating from Underperform to Hold for Nektar Therapeutics (NASDAQ: NKTR).
In other news, WHITFIELD ROY A, Director sold 30,000 shares of the company’s stock on Jun 14. The stock was sold for $17,100 at an average price of $0.57. Upon completion of the transaction, the Director now directly owns 216,250 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President & CEO ROBIN HOWARD W sold 20,361 shares of the business’s stock. A total of $14,660 was realized by selling the stock at an average price of $0.72. This leaves the insider owning 939,797 shares of the company worth $0.94 million. Insiders disposed of 325,608 shares of company stock worth roughly $0.33 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NKTR stock. A new stake in Nektar Therapeutics shares was purchased by MONACO ASSET MANAGEMENT SAM during the first quarter worth $9,261,000. DEEP TRACK CAPITAL, LP invested $1,743,000 in shares of NKTR during the first quarter. In the first quarter, ORBIMED ADVISORS LLC acquired a new stake in Nektar Therapeutics valued at approximately $1,034,000. ACUITAS INVESTMENTS, LLC acquired a new stake in NKTR for approximately $721,000. MOLONEY SECURITIES ASSET MANAGEMENT, LLC purchased a new stake in NKTR valued at around $355,000 in the second quarter. In total, there are 258 active investors with 94.80% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $0.9261 for Nektar Therapeutics (NASDAQ: NKTR). During the past 12 months, Nektar Therapeutics has had a low of $0.51 and a high of $5.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.20, and a quick ratio of 7.90. The fifty day moving average price for NKTR is $0.5836 and a two-hundred day moving average price translates $1.7119 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.73, missing analysts’ expectations of -$0.25 by -0.48. This compares to -$0.49 EPS in the same period last year. The company reported revenue of $21.59 million for the quarter, compared to $24.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.0 percent. For the current quarter, analysts expect NKTR to generate $21.83M in revenue.
Nektar Therapeutics(NKTR) Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
